support@mellalta.com   +1 (304) 470-2225

Metastatic Ovarian Cancer (mOC)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032

$6,500.00$19,500.00

The Metastatic Ovarian Cancer (mOC) market is relatively large with highest market share holding drugs in 2022 i.e., Olaparib and Niraparib. By 2032, the market is expected to change due to the loss of patents of the current therapies and the uptake and launch of new therapies. In a mOC treatment setting, the Olaparib will consistently perform and will grasp the highest market share followed by other emerging drugs. The sales of the emerging therapies for the treatment of mOC in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2018-2032 study period, adding a value estimated at a total market of $ 5.3 billion by 2032.

Clear
SKU: MM202049 Categories: , ,

Description

There has been constant debate among oncologists about how much treatment is too much. Ovarian cancer frequently develops in older women. We often wonder if we should offer our older patients aggressive treatment modalities such as cytoreduction and HIPEC, if the treatment is effective in these women, and if older women have more complications after these complex treatments. Our study suggests that the longevity of patients undergoing cytoreduction plus HIPEC for ovarian cancer was similar regardless of age, and older women were able to recover well from this aggressive treatment.

Ovarian cancer (OC) is the most common cancer in females worldwide and has a high mortality rate. Around 290,000 new OC cases (3.4% of all new cancer cases in females) have been diagnosed annually. Although the 5-year survival rate for ovarian cancer has improved significantly in the past 30 years, the prognosis for ovarian cancer remains poor overall, with a 48.6% 5-year relative survival rate. The prognosis of ovarian cancer is closely related to the stage at diagnosis, as determined according to the staging system developed by the International Federation of Gynecology and Obstetrics (FIGO). Approximately 20%, 5%, 58%, and 17% of women present with stage I, II, III, and IV, respectively. 60% of all cases of ovarian cancer are diagnosed when they are Stage 3. The incidence of ovarian cancer over the lifespan increases from around age 35 to a peak between 55 and 64 years of age.

A Big unmet need in second line patients moving to third line
A Big unmet need in second line patients moving to third line

Metastatic Ovarian Cancer (mOC)– Epidemiology

The total metastatic OC (mOC) incident cases in the G7 countries are anticipated to decline to 42,940 cases by 2032 for the study period (2018- 2032). As per estimates, the United States accounted for the highest incidence of Metastatic Ovarian Cancer (mOC) cases in 2018 which was 18,793 cases and is expected to decline by 2032 for the study period. Among the EU5, Germany had the highest Metastatic Ovarian Cancer (mOC) cases, followed by Italy, France, the UK, and Spain. Japan is reported to have the highest number of cases after the United States.

All the patient’s suffering from aOC will initially have the first line of therapy. However, many patients do not respond well to the first line of treatment and proceed to the second line of therapy.  According to the study by Daniel C. Beachler et.al. 2020, approximately 64 percent of patients who progress following first-line therapy go on to receive a second-line. The patients who will not respond to the second line of therapy will be further treated with the third line of therapy. Approximately 45% of the patients will progress to 3L and 30% of the patients treated with 3L therapy do not respond to it and progress to 4L of therapy.
1L, 2L 3L & 4L/4L+ mOC Treated Cases

Metastatic Ovarian Cancer (mOC)– Current Market Size & Forecast Trends

The metastatic Ovarian Cancer (mOC) therapeutics market is expected to experience high growth throughout our study period (i.e. 2018 to 2032) to USD 9.1 billion, representing  compound annual growth (CAGR) of 12.8%.

The United States captured the highest market share in 2022 as compared to European 5 countries and Japan. We expect that with the launch of the new therapies, the current treatment landscape will grow, catering to the need of the metastatic patient group in all lines. By 2032, the market share of the United States is expected to increase to USD 4.6 billion whereas European 5 countries and Japan will have USD XX billion and USD XX billion market size in 2032 respectively.

Based on the patient’s response to first-line platinum chemotherapy, they are classified as platinum-sensitive (response then relapse after 6-12 months), platinum-resistant (response then relapse within 6-12 months), and platinum-refractory (no response or disease progression after platinum chemotherapy). We expect about 11,000 patients will become platinum- resistant to the first line therapy.

Treatment pattern differences across the United States and EU5 among patients with ovarian cancer.

Despite this recent advancement in the treatment landscape of advanced ovarian cancer, there is considerable overlap in the treatment paradigms for patients with newly diagnosed ovarian cancer and recurrent ovarian cancer. Experts believe that though some patients may develop platinum-resistant ovarian cancer, defined as progression within 6 months of their last treatment with platinum-based chemotherapy, it is possible to utilize platinum again if there was a response. When treating a patient who could respond to platinum-based chemotherapy, options include a carboplatin doublet with or without bevacizumab (Avastin). Typical doublets with bevacizumab may include carboplatin/paclitaxel or carboplatin/gemcitabine.

 

In the 2018-2032 forecast period, we expect a greater  uptake of the new therapies specifically in platinum-resistant ovarian cancer (PROC). The emerging therapies which are expected to enter the market from 2022-2032 period are Mirvetuximab soravtansine/ (ImmunoGen), Ofra-vec (VBL Therapeutics), Upifitimab rilsodotin (Mersana Therapeutics),  Batiraxcept (Aravive, Inc.),  Navicixizumab (OncXerna Therapeutics),  Alpelisib (Novartis Oncology)  Cediranib (AstraZeneca),  Atezolizumab (Genentech),  Relacorilant (Corcept Therapeutics),  Oregovomab (OncoQuest Pharmaceuticals Inc.),  Olvi-Vec (Genelux Corporation),  Catequentinib (Advenchen Laboratories/Jiangsu Chia Tai TianqingPharmaceutical),  Stenoparib (Allarity Therapeutics),  Nemvaleukin Alfa (Alkermes, Inc.), Pembrolizumab (Merck & Co) and Veliparib (AbbVie).

Annual Revenue Metastatic Ovarian Cancer Drugs

 

Report Highlights

  • Metastatic Ovarian Cancer (mOC) – Current Market Trends
  • Metastatic Ovarian Cancer (mOC) – Current & Forecasted Cases across the G7 Countries
  • Metastatic Ovarian Cancer (mOC)– Market Opportunities And Sales Potential for Agents
  • Metastatic Ovarian Cancer (mOC) – Patient-based Market Forecast to 2032
  • Metastatic Ovarian Cancer (mOC) – Untapped Business Opportunities
  • Metastatic Ovarian Cancer (mOC) – Product Positioning Vis-a-vis Competitors’ Products
  • Metastatic Ovarian Cancer (mOC) – KOLs Insight

Additional information

Price

2-3 User License, Enterprise License, Single User License, Site User License

Table of Contents

    • Executive Summary
      • Key Findings
    • Metastatic Ovarian Cancer (mOC) Disease Background
      • Metastatic Ovarian Cancer (mOC) Definition
      • Platinum-sensitive & Platinum-Resistant
      • Symptoms and Causes
      • Stages
    • Metastatic Ovarian Cancer (mOC) Diagnosis
      • Diagnosis & Diagnostic Guidelines
      • Biomarkers
    • Epidemiology and Patient Populations
      • Key Findings
      • Methods and data Sources
        • Country Specific Incident Population with Metastatic Ovarian Cancer (mOC) (US, Germany, France, Italy, Spain, UK, and Japan)
        • Country Specific Treated Cases of Metastatic Ovarian Cancer (mOC) by Line of Therapies
      • Key Sources for Metastatic Ovarian Cancer (mOC) Epidemiology and Model Parameters
        • United States
          • United States Incident Populations with Metastatic Ovarian Cancer (mOC)
          • United States Treated Cases of Metastatic Ovarian Cancer (mOC) by Line of Therapies
        • Germany
          • Germany Incident Populations with Metastatic Ovarian Cancer (mOC)
          • Germany Treated Cases of Metastatic Ovarian Cancer (mOC) by Line of Therapies
        • France
          • France Incident Populations with Metastatic Ovarian Cancer (mOC)
          • France Treated Cases of Metastatic Ovarian Cancer (mOC) by Line of Therapies
        • Italy
          • Italy Incident Populations with Metastatic Ovarian Cancer (mOC)
          • Italy Treated Cases of Metastatic Ovarian Cancer (mOC) by Line of Therapies
        • Spain
          • Spain Incident Populations with Metastatic Ovarian Cancer (mOC)
          • Spain Treated Cases of Metastatic Ovarian Cancer (mOC) by Line of Therapies
        • United Kingdom
          • United Kingdom Incident Populations with Metastatic Ovarian Cancer (mOC)
          • United Kingdom Treated Cases of Metastatic Ovarian Cancer (mOC) by Line of Therapies
        • Japan
          • Japan Incident Populations with Metastatic Ovarian Cancer (mOC)
          • Japan Treated Cases of Metastatic Ovarian Cancer (mOC) by Line of Therapies
    • Current Therapies and Medical Practice
      • Treatments & Medical Practices
      • NCCN Guidelines and Treatment Algorithm
      • ESMO Guidelines and Treatment Algorithm
      • Japan Clinical Treatment Practice and Algorithm
      • ASCO Guidelines
      • Standard Systemic Treatment for Newly Diagnosed Ovarian Cancer
      • Current Standards of Care in Platinum-Resistant Ovarian Cancer
      • PARP Inhibitors Play Important Role in Frontline, Recurrent Maintenance Treatment of Ovarian Cancer
      • KOLs Opinion on Current Treatment Option
    • Metastatic Ovarian Cancer (mOC)- Treatment Studies 
      • Pharmacologic Treatment patterns in the US patients with Advanced Ovarian Cancer (AOC)
      • Treatment pattern differences across the United States and EU5 among patients with ovarian cancer
      • Real-world treatment patterns of patients with advanced (STAGE II-IV) ovarian cancer classified as resistant or refractory to frontline platinum-based therapy
      • Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, in the US and Europe: A Real-World Chart Review Analysis (2017–2020)
      • PARP inhibitor first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database
      • A real-world analysis of the treatment of advanced ovarian cancer with PARPIs
      • Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data
      • Economic Burden of Metastatic Ovarian Cancer in a Commercially Insured Population: A Retrospective Cohort Analysis
      • Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy
    • Unmet Needs
    • Metastatic Ovarian Cancer (mOC)- Marketed Drug Chapters
          •  Olaparib/Lynparza (AstraZeneca)
            • Product Profile
            • Clinical Development
            • Sales & Market Opportunity by 2032
          • Niraparib/Zejula (GSK)
            • Product Profile
            • Clinical Development
            • Sales & Market Opportunity by 2032
          • Rucaparib/Rubraca (Clovis Oncology)
            • Product Profile
            • Clinical Development
            • Sales & Market Opportunity by 2032
    • Emerging Therapies
      • Pipeline Overview
      • Therapeutic Developments Pipeline for Metastatic Ovarian Cancer (mOC)
        • Product Analysis
          • Mirvetuximab soravtansine (ImmunoGen)
            • Product Profile
            • Clinical Development
            • Sales & Market Opportunity by 2032
          • Alpelisib (Novartis Oncology)
            • Product Profile
            • Clinical Development
            • Sales & Market Opportunity by 2032
          • Atezolizumab (Genentech)
            • Product Profile
            • Clinical Development
            • Sales & Market Opportunity by 2032
          • Catequentinib (Advenchen Laboratories/Jiangsu Chia Tai Tianqing Pharmaceutical)
            • Product Profile
            • Clinical Development
            • Sales & Market Opportunity by 2032
          • Upifitimab rilsodotin (Mersana Therapeutics)
            • Product Profile
            • Clinical Development
            • Sales & Market Opportunity by 2032
          • Oregovomab (OncoQuest Pharmaceuticals Inc.)
            • Product Profile
            • Clinical Development
            • Sales & Market Opportunity by 2032
          • Olvi-Vec (Genelux Corporation)
            • Product Profile
            • Clinical Development
          • Nemvaleukin alfa (Alkermes, Inc.)
            • Product Profile
            • Clinical Development
          • Navicixizumab (OncXerna Therapeutics)
            • Product Profile
            • Clinical Development
          • Relacorilant (Corcept Therapeutics)
            • Product Profile
            • Clinical Development
          • Batiraxcept (Aravive, Inc.)
            • Product Profile
            • Clinical Development
          • Pembrolizumab (Merck & Co)
            • Product Profile
            • Clinical Development
          • Cediranib (AstraZeneca)
            • Product Profile
            • Clinical Development
          • Ofra-vec (VBL Therapeutics)
            • Product Profile
            • Clinical Development
          • Veliparib (AbbVie)
            • Product Profile
            • Clinical Development
          • Stenoparib (Allarity Therapeutics)
            • Product Profile
            • Clinical Development
    • Metastatic Ovarian Cancer (mOC)- Pricing & Reimbursement
    • Future Treatment Paradigm
      • Metastatic Ovarian Cancer (mOC) Competitor Landscape and Approvals Anticipated
      • Future Treatment Algorithms and Competitor Positioning
      • Key Data Summary for Emerging Treatment
    • Annual Cost of Current & Emerging Therapies
    • Market Outlook
      • Key Findings
      • Country Specific Market Forecast to 2032
        • Sales of Drugs to Treat Metastatic Ovarian Cancer (mOC) in the Major Pharmaceutical Markets, 2017-2032
        • Patient Share of Metastatic Ovarian Cancer (mOC) Therapies and by Drug
    • Market Forecast by Country
      • United States
        • United States Market for Metastatic Ovarian Cancer (mOC) 2018-2032 (USD Million)
        • United States Market for Metastatic Ovarian Cancer (mOC) by Therapies 2018-2032 (USD Million)
      • Germany
        • Germany Market for Metastatic Ovarian Cancer (mOC) 2018-2032 (USD Million)
        • Germany Market for Metastatic Ovarian Cancer (mOC) by Therapies 2018-2032 (USD Million)
      • France
        • France Market for Metastatic Ovarian Cancer (mOC) 2018-2032 (USD Million)
        • France Market for Metastatic Ovarian Cancer (mOC) by Therapies 2018-2032 (USD Million)
      • Italy
        • Italy Market for Metastatic Ovarian Cancer (mOC) 2018-2032 (USD Million)
        • Italy Market for Metastatic Ovarian Cancer (mOC) by Therapies 2018-2032 (USD Million)
      • Spain
        • Spain Market for Metastatic Ovarian Cancer (mOC) 2018-2032 (USD Million)
        • Spain Market for Metastatic Ovarian Cancer (mOC) by Therapies 2018-2032 (USD Million)
      • United Kingdom
        • United Kingdom Market for Metastatic Ovarian Cancer (mOC) 2018-2032 (USD Million)
        • United Kingdom Market for Metastatic Ovarian Cancer (mOC) by Therapies 2018-2032 (USD Million)
      • Japan
        • Japan Market for Metastatic Ovarian Cancer (mOC) 2018-2032 (USD Million)
        • Japan Market for Metastatic Ovarian Cancer (mOC) by Therapies 2018-2032 (USD Million)
    • Market Drivers and Constraints
      • What Factors Are Driving the Market for Metastatic Ovarian Cancer (mOC)?
      • What Factors Are Constraining the Market for Metastatic Ovarian Cancer (mOC)?
Name
Email
Phone
Enquiry

You may also like…

Get In Touch

Let's keep the conversation going